TGFB1 and hepatocellular carcinoma: In our previous analysis, we also observed an increased expression of TGF-β signaling molecules in CTCs derived from HCC patients resistant to Atezo + Bev therapy [16], suggesting that increased CD90(+) CTCs may reflect activation of the TGF-β pathway in resistant cases.